Durable MRD‐Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia

Introduction Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations. Methods We report the case of a heavily pretreated patient with relapsed/refractory Ph+ ALL treated with blinatumomab and venetoclax without concurrent TKI therapy. Results The patient achieved complete remission and remains in a deep, durable remission exceeding 1 year. Conclusion This case highlights a potential kinase‐independent, TKI‐free strategy for relapsed/refractory Ph+ ALL, warranting further investigation. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission